Indications of Ibrutinib

1.Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Ibrutinib is indicated for the treatment of adult patients with chronic lymphocytic leukemia  (CLL)/small lymphocytic lymphoma (SLL).  

2. Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma with 17p deletion

Ibrutinib is indicated for the treatment of adult patients with chronic lymphocytic leukemia  (CLL)/small lymphocytic lymphoma (SLL) with 17p deletion.  

3. Waldenström’s Macroglobulinemia

Ibrutinib is indicated for the treatment of adult patients with Waldenström’s  macroglobulinemia (WM).  

4. Chronic Graft versus Host Disease

Ibrutinib is indicated for the treatment of adult and pediatric patients age 1 year and older  with chronic graft-versus-host disease (cGVHD) after failure of one or more lines of systemic  therapy.

from FDA，2024.05